- Home
- ENLT vs NVAX Comparison
ENLT vs NVAX Comparison
Compare ENLT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- NVAX
- Stock Information
- Founded
- ENLT 2008
- NVAX 1987
- Country
- ENLT Israel
- NVAX United States
- Employees
- ENLT N/A
- NVAX N/A
- Industry
- ENLT
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENLT
- NVAX Health Care
- Exchange
- ENLT Nasdaq
- NVAX Nasdaq
- Market Cap
- ENLT 2.0B
- NVAX 1.3B
- IPO Year
- ENLT 2023
- NVAX 1995
- Fundamental
- Price
- ENLT $25.18
- NVAX $6.80
- Analyst Decision
- ENLT Buy
- NVAX Buy
- Analyst Count
- ENLT 3
- NVAX 5
- Target Price
- ENLT $19.67
- NVAX $16.60
- AVG Volume (30 Days)
- ENLT 42.9K
- NVAX 5.2M
- Earning Date
- ENLT 08-06-2025
- NVAX 08-07-2025
- Dividend Yield
- ENLT N/A
- NVAX N/A
- EPS Growth
- ENLT 90.47
- NVAX N/A
- EPS
- ENLT 0.98
- NVAX 2.97
- Revenue
- ENLT $397,296,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- ENLT $355.90
- NVAX $56.85
- Revenue Next Year
- ENLT $42.83
- NVAX N/A
- P/E Ratio
- ENLT $24.69
- NVAX $2.29
- Revenue Growth
- ENLT 44.42
- NVAX 25.92
- 52 Week Low
- ENLT $14.01
- NVAX $5.01
- 52 Week High
- ENLT $25.89
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- ENLT 77.00
- NVAX 51.68
- Support Level
- ENLT $22.61
- NVAX $6.23
- Resistance Level
- ENLT $25.89
- NVAX $6.90
- Average True Range (ATR)
- ENLT 0.49
- NVAX 0.30
- MACD
- ENLT 0.35
- NVAX 0.01
- Stochastic Oscillator
- ENLT 90.74
- NVAX 67.00
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.